These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 39060201)

  • 41. Routine childhood vaccination rates in an academic family health team before and during the first wave of the COVID-19 pandemic: a pre-post analysis of a retrospective chart review.
    Dong A; Meaney C; Sandhu G; De Oliveira N; Singh S; Morson N; Forte M
    CMAJ Open; 2022; 10(1):E43-E49. PubMed ID: 35078822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving pandemic preparedness through better, faster influenza vaccines.
    Newland M; Durham D; Asher J; Treanor JJ; Seals J; Donis RO; Johnson RA
    Expert Rev Vaccines; 2021 Mar; 20(3):235-242. PubMed ID: 33576708
    [No Abstract]   [Full Text] [Related]  

  • 43. COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions.
    Tagoe ET; Sheikh N; Morton A; Nonvignon J; Sarker AR; Williams L; Megiddo I
    Front Public Health; 2021; 9():709127. PubMed ID: 34422750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies to Enhance COVID-19 Vaccine Uptake among Prioritized Groups, Uganda-Lessons Learned and Recommendations for Future Pandemics.
    Kiiza D; Semanda JN; Kawere BB; Ajore C; Wasswa CK; Kwiringira A; Tumukugize E; Sserubidde J; Namyalo N; Wadria RB; Mukiibi P; Kasule J; Chemos I; Ruth AW; Atugonza R; Banage F; Wibabara Y; Ampaire I; Driwale A; Vosburgh W; Nelson L; Lamorde M; Boore A
    Emerg Infect Dis; 2024 Jul; 30(7):1326-1334. PubMed ID: 38916545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023.
    Marron L; Mateo-Urdiales A; O'Donnell J; Robinson E; Domegan L
    Euro Surveill; 2024 Jul; 29(28):. PubMed ID: 38994604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparing the public for COVID-19 vaccines: How can general practitioners build vaccine confidence and optimise uptake for themselves and their patients?
    Danchin M; Biezen R; Manski-Nankervis JA; Kaufman J; Leask J
    Aust J Gen Pract; 2020 Oct; 49(10):625-629. PubMed ID: 33015676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
    Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.
    Aizawa Y; Sato I; Abe Y; Sasagawa F; Saitoh A
    Vaccine; 2024 Aug; 42(21):126137. PubMed ID: 39048467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccine optimization for COVID-19: Who to vaccinate first?
    Matrajt L; Eaton J; Leung T; Brown ER
    Sci Adv; 2020 Feb; 7(6):. PubMed ID: 33536223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing vaccination priorities for different ages and age-specific vaccination strategies of COVID-19 using an SEIR modelling approach.
    Yang C; Yang Y; Li Y
    PLoS One; 2021; 16(12):e0261236. PubMed ID: 34936650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity.
    Han S; Cai J; Yang J; Zhang J; Wu Q; Zheng W; Shi H; Ajelli M; Zhou XH; Yu H
    Nat Commun; 2021 Aug; 12(1):4673. PubMed ID: 34344871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19 vaccines and vaccination program for aging adults.
    Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6719-6730. PubMed ID: 34787877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses.
    Tomalka JA; Suthar MS; Deeks SG; Sekaly RP
    Nat Immunol; 2022 Mar; 23(3):360-370. PubMed ID: 35210622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19 vaccination uptake in remote areas-Evidence from a panel survey in Bangladesh.
    Rudolph L; Koubi V; Freihardt J
    PLoS One; 2024; 19(8):e0305659. PubMed ID: 39121025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
    Dal-Ré R; Bekker LG; Gluud C; Holm S; Jha V; Poland GA; Rosendaal FR; Schwarzer-Daum B; Sevene E; Tinto H; Voo TC; Sreeharan N
    Lancet Infect Dis; 2021 Nov; 21(11):e342-e347. PubMed ID: 34019801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study.
    Wang W; Wu Q; Yang J; Dong K; Chen X; Bai X; Chen X; Chen Z; Viboud C; Ajelli M; Yu H
    BMJ; 2020 Dec; 371():m4704. PubMed ID: 33323388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ethnic and minority group differences in engagement with COVID-19 vaccination programmes - at Pandemic Pace; when vaccine confidence in mass rollout meets local vaccine hesitancy.
    Reid JA; Mabhala MA
    Isr J Health Policy Res; 2021 May; 10(1):33. PubMed ID: 34044891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.